Antigenic peptide chain group for treating tumor and application of antigenic peptide chain group in medicine

A technology of antigenic peptides and drugs, applied in the field of malignant tumor bioimmune drugs, can solve problems such as hearing loss, side effects, blurred vision, etc., and achieve the effect of low incidence of side effects, killing tumor cells, and obvious changes

Inactive Publication Date: 2018-09-04
天津亨佳生物科技发展有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are many methods of biological immunotherapy for tumors, including common CIK cell immunotherapy, DC drug therapy, etc., but the therapeutic effect is not significant, and the survival rate of patients has not been significantly improved
In addition, immune cells stimulated by non-mutated tumor highly expressed proteins have been studied for anti-tumor immune responses, but due to their non-specific expression, there are side effects, including blurred vision, hearing loss, rash, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigenic peptide chain group for treating tumor and application of antigenic peptide chain group in medicine
  • Antigenic peptide chain group for treating tumor and application of antigenic peptide chain group in medicine
  • Antigenic peptide chain group for treating tumor and application of antigenic peptide chain group in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Patient A, female, 66 years old. Breast cancer lung metastasis, brain metastasis, clinical stage IV, vinorelbine single-agent chemotherapy progressed after 4 times, targeted drug resistance. After multiple metastatic lesions in the lung, a biopsy of the lung lesions was performed. After whole exome sequencing and HLA typing chip detection, the patient carried HER2 (ERBB2) exon 20 insertion mutation, HLA typing was HLA-A: A* 3203A*3201; HLA-B: B*3015B*3102; HLA-C: C*0325C*0512; HLA-DQB1: DQB1*0202DQB1*1122; HLA-DRB1: DRB1*0203DRB1*0401.

[0027] The specific tumor antigen peptide chain SEQ ID No: 1 of the present invention is used for treatment once a week for 12 weeks. Detect the specific CD8+Tetramer+T cell secretion by spot detection before and after injection of the antigen peptide chain group (hereinafter referred to as "drug"), and observe the changes in tumor size 12 weeks before and after the drug by imaging. The results are as follows figure 1 with figure 2 Shown...

Embodiment 2

[0032] Patient B, male, 72 years old, had lung metastases after gastric cancer surgery, received 6 weeks of chemotherapy with oxaliplatin + capecitabine, and then progressed. After intrapulmonary metastasis biopsy for whole exome sequencing and HLA typing chip detection, the patient carries HER2 (ERBB2) exon 20 insertion mutation, HLA typing is HLA-A: A*0301A*3501; HLA-B: B*0201B*3201; HLA-C: C*0333C*0301; HLA-DQB1: DQB1*0301DQB1*0320; HLA-DRB1: DRB1*0323DRB1*1222.

[0033] The antigen peptide chain SEQ ID No: 2 for treating tumors of the present invention is used for combination therapy once a week for 12 weeks.

[0034] Changes in the size of lung metastases before and after treatment such as image 3 Shown by image 3 It can be seen that before treatment, the size of the right lung tumor is 4cm×5cm ( image 3 -A); 12 weeks after treatment, the right lung tumor basically disappeared ( image 3 -B) The tumor is significantly reduced and the density becomes lighter than before ...

Embodiment 3-101

[0036] Example 3-101 Different types and different levels of cancer patients were selected. After whole exome sequencing and HLA typing chip detection, the patients were all patients with HER2 (ERBB2) exon 20 insertion mutation, and they used different antigens. The combination form of peptide chain group is treated once a week for 12 weeks. The HLA*A3101-HVKITDFGRTetramer staining results of Example 3-101 and the changes in lung tumor size before and after treatment are similar to those of Example 1-2. Due to space limitations, the details are not repeated here. The above results all show that the antigen peptide chain group of the present invention can induce tumor dendritic cells, and dendritic cells as antigen presenting cells can present antigen information to T cells, interact with T cells, and make T cells produce It specifically kills tumor cells, plays a role in killing tumor cells, and the effect is obvious.

[0037] During the treatment of Example 1-101, ELISA was use...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an antigenic peptide chain group for a tumor individualized biological immunotherapy and application of the antigenic peptide chain group in medicine. The antigenic peptide chain group for treating the tumor comprises a combination of any one or at least two amino acid sequences as shown in the SEQ ID No:1-101. The antigenic peptide chain group, provided by the invention, can induce tumor-producing dendritic cells; therefore, the dendritic cells serving as antigen-presenting cells can present antigen information to T cells, interact with the T cells, and lead the T cells to produce specific killing tumor cells, thereby playing a role of killing the tumor cells.

Description

Technical field [0001] The invention belongs to the technical field of malignant tumor bioimmune drugs, and particularly relates to an antigen peptide chain group for tumor individualized bioimmunotherapy and its application in medicine. Background technique [0002] At present, the global incidence of malignant tumors is on the rise, with high mortality and poor prognosis. The National Cancer Center's National Cancer Research Office published the largest cancer survival data in China in the International Journal of Cancer. The data shows that the 5-year cancer survival rate in China is 30.9%, which is much lower than the level of developed countries. At the same time, the survival rate of rural patients is only For half of urban patients. In developed countries, prostate cancer and breast cancer account for the majority. In China, lung cancer, stomach cancer, liver cancer and other cancers are more common. The cancer with the highest incidence and mortality is lung cancer. Tra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08A61K39/00A61P35/00
CPCC07K7/06A61K39/00A61K39/0011A61P35/00C07K7/08A61K2300/00
Inventor 刘玉强李晓丹
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap